Intrauterine contraceptive devices (IUD) are inserted into the uterus in order to prevent pregnancy. Increasing unplanned pregnancies, unprotected sex, and family planning initiatives around the world have made IUDs a popular choice among women. As per WHO, contraceptive use has been increased globally, especially in Asia and Latin America. The use of contraception has risen from 54% in 1990 to 57.4% in 2015. In Asia, it has risen from 60.9% to 61.8%.
Increasing government initiatives and world institutions have opted for this method to reduce the number of abortions, unwanted pregnancies and as a measure of population control. As per United Nations, in 2017, 63% of women were using some form of contraception. Contraceptive use was above 70% in Europe, Latin America & the Caribbean, and Northern America. It was below 25% in Middle & Western Africa.
Government-funded programs in developed regions for family planning have paved the way for IUD's growth in the market. For instance, U.S. funding for family planning and reproductive health which includes the U.S. contribution to the United Nations Population Fund (UNFPA) was USD 608 million in FY 2018.
New products in the market are strengthening the position of IUDs such as Kyleena, manufactured by Bayer and the newest IUD received approval from the FDA in 2016. It has lower hormone levels than Mirena.
The global intrauterine contraceptive devices (IUD) market accounted for over USD 2,951.5 million in 2017 and is expected to grow at a CAGR of 10.5% during the forecast period, 2019–2026.
The global intrauterine contraceptive devices market is segmented by type, products, and end-user.
By type, the market is segmented into hormonal intrauterine devices and copper intrauterine devices. The hormonal intrauterine device segment is expected to grow at the fastest CAGR. The growth can be attributed to a low failure rate as compared to copper IUD.
Based on products, the global intrauterine contraceptive devices market is segmented into Mirena, Skyla, paragard, essure, levosert, and others. Mirena is expected to generate the largest revenue due to its high availability in the market.
End-user segment is classified into hospitals, gynecology clinics, and community healthcare centers. The hospital's segment can hold the largest share of the market due to an increase in visits to the hospitals for checkups and improving healthcare infrastructure in emerging countries.
Geographically, the global intrauterine contraceptive devices market is segmented into four regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa (LAMEA).
Europe is likely to dominate the intrauterine contraceptive devices market due to the high adoption of IUDs over oral contraceptives. IUDs are highly effective and have fewer systemic effects. Europe possesses the least fertility rate in the world. The average for the region is 1.4 children per couple.
North America is likely to emerge as the second-largest intrauterine contraceptive devices market globally. This can be attributed to high awareness among women and IUDs' longer-lasting and highly effective solutions. As per National Center for Health Statistics (NCHS), women preferred long-lasting intrauterine devices (IUD) over other methods. Furthermore, IUD use increased 83% from 2011– to 2013.
Asia pacific surgical suture market is expected to witness significant growth on account of increasing demand for family planning to control the population. As per the United Nations report 2015, in Asia, the highest levels of contraceptives were used in the Eastern and South-Eastern regions. In 10 countries, the contraceptive prevalence in 2015 was 70% with the highest of 83 in China. The lowest level of contraceptive prevalence in Asia was in Afghanistan at 29%.
LAMEA is expected to witness moderate growth owing to a lack of awareness and unmet demands. As per the United Nations report, sub-Saharan Africa, had the highest unmet need 24 percent, double the world average in 2015. In general, unmet need is high where contraceptive prevalence is low. In addition, most countries in Latin America and the Caribbean had a moderate level of contraceptive use.
Some of the key players in the global intrauterine contraceptive devices market are Agile Therapeutics, Bayer Healthcare, Fuji Latex Co. Ltd, Pfizer, Reckitt Benckiser Group PLC, Mylan Laboratories, Merck & Co., and Okamato Industries Inc.
|Market Size||USD in Billion By 2030|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
|Segments Covered||by Type, Size, Market Trends, Products, End User|
|Geographies Covered||North America, Europe, Asia-Pacific, LAME and Rest of the World|
|Key Companies Profiled/Vendors||Agile Therapeutics, Bayer Healthcare, Fuji Latex Co. Ltd, Pfizer, Reckitt Benckiser Group PLC, Mylan Laboratories, Merck & Co., and Okamato Industries Inc.,|
|Key Market Opportunities||The Healthcare It Industry'S Substantial Growth Fuels The Intrauterine Contraceptive Devices (Iud) Market|